Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5

Authors: Caroline MM van Geelen, Bodvael Pennarun, Phuong TK Le, Elisabeth GE de Vries, Steven de Jong

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

rhTRAIL is a therapeutic agent, derived from the TRAIL cytokine, which induces apoptosis in cancer cells by activating the membrane death receptors 4 and 5 (DR4 and DR5). Here, we investigated each receptor's contribution to rhTRAIL sensitivity and rhTRAIL resistance. We assessed whether agonistic DR4 or DR5 antibodies could be used to circumvent rhTRAIL resistance, alone or in combination with various chemotherapies.

Methods

Our study was performed in an isogenic model comprised of the SW948 human colon carcinoma cell line and its rhTRAIL resistant sub-line SW948-TR. Effects of rhTRAIL and agonistic DR4/DR5 antibodies on cell viability were measured using MTT assays and identification of morphological changes characteristic of apoptosis, after acridine orange staining. Sensitivity to the different death receptor ligands was stimulated using pretreatment with the cytokine IFN-gamma and the proteasome inhibitor MG-132. To investigate the mechanisms underlying the changes in rhTRAIL sensitivity, alterations in expression levels of targets of interest were measured by Western blot analysis. Co-immunoprecipitation was used to determine the composition of the death-inducing signalling complex at the cell membrane.

Results

SW948 cells were sensitive to all three of the DR-targeting agents tested, although the agonistic DR5 antibody induced only weak caspase 8 cleavage and limited apoptosis. Surprisingly, agonistic DR4 and DR5 antibodies induced equivalent DISC formation and caspase 8 cleavage at the level of their individual receptors, suggesting impairment of further caspase 8 processing upon DR5 stimulation. SW948-TR cells were cross-resistant to all DR-targeting agents as a result of decreased caspase 8 expression levels. Caspase 8 protein expression was restored by MG-132 and IFN-gamma pretreatment, which also re-established sensitivity to rhTRAIL and agonistic DR4 antibody in SW948-TR. Surprisingly, MG-132 but not IFN-gamma could also increase DR5-mediated apoptosis in SW948-TR.

Conclusions

These results highlight a critical difference between DR4- and DR5-mediated apoptotic signaling modulation, with possible implications for future combinatorial regimens.
Appendix
Available only for authorised users
Literature
1.
Kelley SK, Ashkenazi A: Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol. 2004, 4: 333-339. 10.1016/j.coph.2004.02.006.CrossRefPubMed
2.
Oldenhuis CNAM, Stegehuis JH, Walenkamp AME, de Jong S, de Vries EGE: Targeting TRAIL death receptors. Current Opinion in Pharmacology. 2008, 8: 433-439. 10.1016/j.coph.2008.06.011.CrossRefPubMed
3.
Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008, 8: 915-928. 10.1038/nrc2536.CrossRefPubMed
4.
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999, 5: 157-163. 10.1038/5517.CrossRefPubMed
5.
Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, et al: Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA. 2000, 97: 1754-1759. 10.1073/pnas.030545097.CrossRefPubMedPubMedCentral
6.
Gliniak B, Le T: Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 1999, 59: 6153-6158.PubMed
7.
Shankar S, Singh TR, Srivastava RK: Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate. 2004, 61: 35-49. 10.1002/pros.20069.CrossRefPubMed
8.
Singh TR, Shankar S, Chen X, Asim M, Srivastava RK: Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 2003, 63: 5390-5400.PubMed
9.
Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, et al: Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res. 2003, 9: 3731-3741.PubMed
10.
Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H, et al: Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol. 2001, 166: 4891-4898.CrossRefPubMed
11.
Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, et al: Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 2001, 7: 954-960. 10.1038/91000.CrossRefPubMed
12.
Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T, et al: TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol. 2003, 171: 1061-1069.CrossRefPubMed
13.
Kelley SK, Harris LA, Xie D, DeForge L, Totpal K, Bussiere J, et al: Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther. 2001, 299: 31-38.PubMed
14.
Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al: Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res. 2007, 13: 6187-6194. 10.1158/1078-0432.CCR-07-0950.CrossRefPubMed
15.
Tolcher AW, Mita M, Meropol NJ, von MM, Patnaik A, Padavic K, et al: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol. 2007, 25: 1390-1395. 10.1200/JCO.2006.08.8898.CrossRefPubMed
16.
Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, et al: Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol. 2005, 130: 501-510. 10.1111/j.1365-2141.2005.05656.x.CrossRefPubMed
17.
Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, DeForge L, et al: Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem. 2005, 280: 2205-2212. 10.1074/jbc.M410660200.CrossRefPubMed
18.
Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, et al: Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res. 2004, 10: 3207-3215. 10.1158/1078-0432.CCR-03-0494.CrossRefPubMed
19.
Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P: Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem. 2001, 276: 46639-46646. 10.1074/jbc.M105102200.CrossRefPubMed
20.
Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006, 26: 7046-7055. 10.1128/MCB.00520-06.CrossRefPubMedPubMedCentral
21.
Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, et al: Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol. 1999, 162: 2597-2605.PubMed
22.
Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer. 2005, 92: 1430-1441. 10.1038/sj.bjc.6602487.CrossRefPubMedPubMedCentral
23.
Thomas LR, Johnson RL, Reed JC, Thorburn A: The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J Biol Chem. 2004, 279: 52479-52486. 10.1074/jbc.M409578200.CrossRefPubMed
24.
He Q, Huang Y, Sheikh MS: Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene. 2004, 23: 2554-2558. 10.1038/sj.onc.1207351.CrossRefPubMed
25.
Ruiz de Almodovar C, Lopez-Rivas A, Ruiz-Ruiz C: Interferon-gamma and TRAIL in human breast tumor cells. Vitam Horm. 2004, 67: 291-318. full_text.CrossRefPubMed
26.
Yang X, Merchant MS, Romero ME, Tsokos M, Wexler LH, Kontny U, et al: Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res. 2003, 63: 1122-1129.PubMed
27.
Fulda S, Debatin KM: 5-Aza-2[prime]-deoxycytidine and IFN-[gamma] cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene. 2006, 25: 5125-5133. 10.1038/sj.onc.1209608.CrossRefPubMed
28.
Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB: The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis. 2006, 11: 1175-1193. 10.1007/s10495-006-8048-9.CrossRefPubMed
29.
Li W, Zhang X, Olumi AF: MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res. 2007, 67: 2247-2255. 10.1158/0008-5472.CAN-06-3793.CrossRefPubMed
30.
Merchant MS, Yang X, Melchionda F, Romero M, Klein R, Thiele CJ, et al: Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res. 2004, 64: 8349-8356. 10.1158/0008-5472.CAN-04-1705.CrossRefPubMed
31.
Varela N, Munoz-Pinedo C, Ruiz-Ruiz C, Robledo G, Pedroso M, Lopez-Rivas A: Interferon-gamma sensitizes human myeloid leukemia cells to death receptor-mediated apoptosis by a pleiotropic mechanism. J Biol Chem. 2001, 276: 17779-17787. 10.1074/jbc.M100815200.CrossRefPubMed
32.
Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ, et al: Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther. 2005, 4: 781-786. 10.1158/1535-7163.MCT-04-0330.CrossRefPubMedPubMedCentral
33.
van Geelen CM, Pennarun B, Boerma-Van EW, Le PT, Spierings DC, De Vries EG, et al: Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines. Int J Oncol. 2010, 37: 1031-1041.PubMed
34.
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999, 104: 155-162. 10.1172/JCI6926.CrossRefPubMedPubMedCentral
35.
Leibovitz A, Stinson JC, McCombs WB, McCoy CE, Mazur KC, Mabry ND: Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 1976, 36: 4562-4569.PubMed
36.
van Geelen CMM, de Vries EGE, Le TKP, van Weeghel RP, de Jong S: Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer. 2003, 89: 363-373. 10.1038/sj.bjc.6601065.CrossRefPubMedPubMedCentral
37.
Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, et al: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol. 2000, 2: 241-243. 10.1038/35008667.CrossRefPubMed
38.
Krammer PH, Arnold R, Lavrik IN: Life and death in peripheral T cells. Nat Rev Immunol. 2007, 7: 532-542. 10.1038/nri2115.CrossRefPubMed
39.
Hougardy BM, Maduro JH, van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EGE, et al: Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer. 2006, 118: 1892-1900. 10.1002/ijc.21580.CrossRefPubMed
40.
Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, et al: Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res. 2005, 65: 5662-5667. 10.1158/0008-5472.CAN-05-0693.CrossRefPubMed
41.
Johnsen JI, Pettersen I, Ponthan F, Sveinbjornsson B, Flaegstad T, Kogner P: Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL. Int J Oncol. 2004, 25: 1849-1857.PubMed
42.
Pennarun B, Meijer A, de Vries EGE, Kleibeuker JH, Kruyt FA, de Jong S: Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2010, 1805: 123-140. 10.1016/j.bbcan.2009.11.004.CrossRef
43.
Leverkus M, Sprick MR, Wachter T, Denk A, Brocker EB, Walczak H, et al: TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2. J Invest Dermatol. 2003, 121: 149-155. 10.1046/j.1523-1747.2003.12332.x.CrossRefPubMed
44.
van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, et al: Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA. 2006, 103: 8634-8639. 10.1073/pnas.0510187103.CrossRefPubMedPubMedCentral
45.
Pennarun B, Kleibeuker J, Oenema T, Stegehuis JH, Vries EGE, de Jong S: Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL. Anal Cell Pathol. 2010, 33: 229-244.CrossRef
46.
Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, et al: Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell. 2009, 137: 721-735. 10.1016/j.cell.2009.03.015.CrossRefPubMed
47.
Yang X, Merchant MS, Romero ME, Tsokos M, Wexler LH, Kontny U, et al: Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res. 2003, 63: 1122-1129.PubMed
48.
Ashkenazi A: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002, 2: 420-430. 10.1038/nrc821.CrossRefPubMed
49.
Geller J, Petak I, Szucs KS, Nagy K, Tillman DM, Houghton JA: Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin. Clin Cancer Res. 2003, 9: 6504-6515.PubMed
50.
Langaas V, Shahzidi S, Johnsen JI, Smedsrod B, Sveinbjornsson B: Interferon-gamma modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res. 2001, 21: 3733-3738.PubMed
51.
Lavrik IN, Golks A, Riess D, Bentele M, Eils R, Krammer PH: Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J Biol Chem. 2007, 282: 13664-13671. 10.1074/jbc.M700434200.CrossRefPubMed
52.
Smith MR, Jin F, Joshi I: Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res. 2007, 13: 5528s-5534s. 10.1158/1078-0432.CCR-07-0982.CrossRefPubMed
53.
Koschny R, Sykora J, Walczak H, Ganten T, Haas T, Sprick M, et al: Bortezomib-Mediated Up-Regulation of TRAIL-R1 and TRAIL-R2 Is Not Necessary for but Contributes to Sensitization of Primary Human Glioma Cells to TRAIL. Clin Cancer Res. 2007, 13: 6541-6542. 10.1158/1078-0432.CCR-07-1759.CrossRef
54.
Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, et al: The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007, 67: 4981-4988. 10.1158/0008-5472.CAN-06-4274.CrossRefPubMed
55.
Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD: Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene. 2004, 23: 2009-2015. 10.1038/sj.onc.1207373.CrossRefPubMed
Metadata
Title
Modulation of TRAIL resistance in colon carcinoma cells: Different contributions of DR4 and DR5
Authors
Caroline MM van Geelen
Bodvael Pennarun
Phuong TK Le
Elisabeth GE de Vries
Steven de Jong
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-39

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Expression of delta-catenin is associated with progression of human astrocytoma

Research article

Identification of area-level influences on regions of high cancer incidence in Queensland, Australia: a classification tree approach

Research article

MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo

Research article

Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation

Research article

Circulating levels of cell adhesion molecule L1 as a prognostic marker in gastrointestinal stromal tumor patients

Research article

Lung cancer stage at diagnosis: Individual associations in the prospective VITamins and lifestyle (VITAL) cohort
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits